ArticleExtracellular vesicles and circulating nucleic acids2025
A new hope for pulmonary hypoplasia: amniotic fluid stem cell extracellular vesicles?
Article in Extracellular vesicles and circulating nucleic acids, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Amniotic Fluid Stem Cells in Birth Defects: Integrated Roles in Disease Modeling, Prenatal Diagnosis, and Therapy.Stem cell reviews and reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In a recent study, Antounians and colleagues (2024) investigated the potential of amniotic fluid stem cell-derived extracellular vesicles (AFSC-EVs) as a therapeutic intervention for pulmonary hypoplasia resulting from congenital diaphragmatic hernia (CDH). They demonstrated the pronounced inflammatory signature of the fetal hypoplastic lungs, marked by heightened macrophage density in a CDH rat model. Intra-amniotic AFSC-EV administration mitigated the inflammatory process and enhanced fetal lung development by promoting branching morphogenesis and epithelial maturation. These findings add to a growing body of preclinical and clinical evidence supporting the therapeutic potential of AFSC-EVs for inflammation-driven pathologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.